Diagnostic Criteria for Acute Kidney Injury
Acute kidney injury is diagnosed when a patient meets ANY of the KDIGO Stage 1 criteria: serum creatinine rise ≥0.3 mg/dL (≥26 μmol/L) within 48 hours OR ≥50% increase from baseline within 7 days OR urine output <0.5 mL/kg/h for >6 hours. 1
KDIGO Staging System
The current gold standard uses the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, which merged the earlier RIFLE and AKIN classifications 1. This system provides both diagnostic and severity stratification:
Stage 1 (Initial Diagnosis)
- Creatinine: Rise ≥0.3 mg/dL (≥26 μmol/L) within 48 hours OR 50-99% increase from baseline within 7 days (1.5-1.99× baseline)
- Urine output: <0.5 mL/kg/h for >6 hours
Stage 2
- Creatinine: 100-199% increase from baseline within 7 days (2.0-2.99× baseline)
- Urine output: <0.5 mL/kg/h for >12 hours
Stage 3
- Creatinine: ≥200% increase from baseline within 7 days (≥3.0× baseline) OR creatinine ≥4.0 mg/dL (≥354 μmol/L) with documented acute rise OR any requirement for renal replacement therapy
- Urine output: <0.3 mL/kg/h for 24 hours OR anuria for 12 hours
Key Diagnostic Principles
Patients are classified by the highest stage criterion met, using either creatinine OR urine output—whichever is worse 1. The small 0.3 mg/dL rise criterion was added because studies demonstrated this seemingly minor elevation independently predicts approximately fourfold increased hospital mortality 1.
Critical Timing Elements
The "acute" component requires documentation that changes occurred within specified timeframes 1:
- 48-hour window for the 0.3 mg/dL rise
- 7-day window for percentage-based creatinine increases
- Real-time monitoring for urine output criteria
Initial detection must occur in real-time when criteria are first met, while staging is performed retrospectively at episode completion using peak values 1.
Comparative Performance
The KDIGO criteria identify more AKI cases than RIFLE (51% vs 46.9%) or AKIN (51% vs 38.4%) in critically ill populations 2. KDIGO demonstrates superior predictive ability for in-hospital mortality compared to RIFLE (AUC 0.757 vs 0.738), though performs similarly to AKIN 2. All three systems show significantly elevated mortality in diagnosed patients versus non-AKI patients (27.4-32.2% vs 5.6-7.1%) 2.
Important Caveats
Baseline Creatinine Issues
When baseline creatinine is unknown, presume it occurred within 7 days based on patient history 1. The Stage 3 modification creates a controversial situation: a rise to creatinine ≥4.0 mg/dL automatically qualifies as Stage 3 in CKD patients but only Stage 1 in patients without CKD if the absolute rise is small 1.
Oliguria Considerations
Patients manifesting both oliguria and azotemia have worse disease severity and outcomes than those with isolated criteria 3. Never automatically fluid-load in response to oliguria alone—interpret urine output alongside hemodynamic parameters.
Limitations of Current Criteria
Approximately 35% of biopsy-proven acute diffuse parenchymal pathology fails to meet KDIGO criteria, primarily due to slow creatinine rises 1. The criteria assume adequate fluid resuscitation and exclusion of urinary obstruction, though KDIGO does not explicitly mandate this verification 1.
Biomarker Context
While novel biomarkers (NGAL, KIM-1, TIMP-2·IGFBP7, cystatin C) show promise for earlier detection and risk stratification 3, 4, 5, the current diagnostic standard remains creatinine and urine output-based KDIGO criteria 1. Biomarkers should only be used when results will change management within an actionable response pathway.